Neonmind Retains Renmark Financial Communications for IR services
NeonMind Retains Renmark Financial Communications Inc.
Vancouver, B.C. – February 3, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FRA: 6UF)
(“NeonMind”), a psychedelic drug development company, is pleased to announce that it has retained
the services of Renmark Financial Communications Inc. (“Renmark”) for certain investor relations
activities.
“We are pleased to announce that we have selected Renmark to reinforce NeonMind's profile in the
financial community and enhance the visibility of our company. We choose Renmark because its
standards and methodologies fit well with the message we wish to communicate to the investing
public,” noted Rob Tessarolo, NeonMind President & CEO.
Renmark is expected to supplement the existing investor relations program by including a focus on
institutions and brokerage firms that will expand the target investor audience of the Company.
In consideration of the services to be provided, the monthly fees incurred by NeonMind will be a cash
consideration of up to $7,000 CAD, for a period of three months ending on April 7th, 2021, and monthly
thereafter.
Renmark Financial Communications does not have any interest, directly or indirectly, in NeonMind its
securities, or any right or intent to acquire such an interest.
About NeonMind Biosciences Inc.
NeonMind is a preclinical psychedelic drug development company. Its first proposed drug candidate
involves the administration of psilocybin (a complex organic compound found in psychedelic
mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a
preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent
applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating
obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin
and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in
conjunction with therapy or other treatments. NeonMind is also pursuing commercialization of its
catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four
mushroom‐infused coffees containing medicinal mushrooms Lion’s Mane, Turkey Tail, Reishi and
Cordyceps which are available for purchase online in Canada at www.neonmind.com.
For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind
mushroom infused coffee at www.NeonMind.com.
Rob Tessarolo, President & CEO
Tel: 416‐750‐3101
Investor Relations:
Edge Communications
Tel: 1‐866‐318‐6874
Renmark Financial Communications Inc.
Melanie Barbeau: `
Tel: 416‐644‐2020 or 212‐812‐7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news
release.
Cautionary Statement Regarding Forward‐Looking Statements
This press release includes forward‐looking information and statements (collectively, “forward looking
statements”) under applicable Canadian securities legislation. Forward‐looking statements are
necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause
actual results and future events to differ materially from those expressed or implied by such forward‐
looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to
the development, testing, licensing, intellectual property protection, the potential for not acquiring any
rights as a result of the patent application and any products making use of the intellectual property may
be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be
required before commercial exploitation of the intellectual property can happen. The laws around
cultivating, selling and using psychedelic mushrooms would need to change in most jurisdictions in order
for the use of psychedelic products to be legal and sale of, and demand for NeonMind products, general
business, economic, competitive, political and social uncertainties, delay or failure to receive board or
regulatory approvals where applicable, and the state of the capital markets. NeonMind cautions readers
not to place undue reliance on forward‐looking statements provided by NeonMind, as such forward‐
looking statements are not a guarantee of future results or performance and actual results may differ
materially. The forward‐looking statements contained in this press release are made as of the date of
this press release, and NeonMind expressly disclaims any obligation to update or alter statements
containing any forward‐looking information, or the factors or assumptions underlying them, whether as
a result of new information, future events or otherwise, except as required by law.